January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

Real-time index price for KBW Insurance Index (KIX), along with buy or sell indicators, analysis, charts, historical ...

Industry watchers expect global biotech mergers and acquisition activity to strengthen in 2025 after a subdued 2024, aiding ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn ... s Skyrizi and an expected approval for Johnson & Johnson’s Tremfya raises questions about ...

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Johnson & Johnson announced it will buy Intra-Cellular Therapies for $14.6 billion. Biogen said it will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece.

A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

Eli Lilly will buy Boston biotech Scorpion Therapeutics ... including one involving another oncology biotech—that of the Johnson and Johnson acquiring Intracellular Therapies.

Eli Lilly CEO David Ricks joins 'Squawk on the ... Tom Brady and the Raiders didn’t get Ben Johnson. Now what?